Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis
Open Access
- 1 October 1996
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 39 (10) , 1747-1753
- https://doi.org/10.1002/art.1780391019
Abstract
Objective. To determine if circulating gelatinase activity and matrix metalloproteinase 9 (MMP-9) (gelatinase B, or 92-kd type IV collagenase) antigenic levels are elevated in sera of patients with giant cell arteritis (GCA), and to ascertain if MMP-9 messenger RNA (mRNA) is deposited in situ at sites of disease involvement. Methods. Serum samples were collected from 12 patients with GCA and 12 healthy volunteers. Vascular tissue was obtained at the time of temporal artery biopsy. Type IV collagenase activity was determined by gelatin substrate zymography and the quantitative biotinylated gelatin substrate degradation assay. A double-sandwich immunoassay utilizing 2 different isotypes of monoclonal antibodies generated against MMP-9 was used for measuring serum MMP-9 antigenic levels. Finally, to localize sites of MMP-9 mRNA transcription in inflamed arteries, the method of reverse transcriptase in situ polymerase chain reaction (RTisPCR) was utilized. Results. Serum gelatinase activity and MMP-9 titers were significantly increased in patients with GCA (mean ± SEM 198.9 ± 36.9 μg gelatin/hour/ml serum, versus 21.2 ± 4.0 in controls; P = 0.0006). The differences in antigenic MMP-9 levels were even more prominent (3005.4 ± 900.6 ng/ml and 31.6 ± 9.8 ng/ml in GCA and control sera, respectively; P = 0.007). By RTisPCR, MMP-9 mRNA was mainly detected in cytoplasm of cells resembling smooth muscle cells and fibroblasts in regions of fragmented elastic tissue in the lamina media. Conclusion. Gelatinase activity, and specifically MMP-9 levels, are substantially elevated in sera of patients with GCA. Detection of MMP-9 mRNA in the lamina media of inflamed vasculature suggests that degradation of intercellular matrix, particularly elastic fibers, may play a key role in the pathogenesis of GCA. Further studies are needed to determine if the circulating MMP-9 level could be utilized as a clinical marker of disease activity.Keywords
This publication has 30 references indexed in Scilit:
- Monoclonal Antibodies to Human MMP‐9Annals of the New York Academy of Sciences, 1994
- Giant cell arteritisArchives of Family Medicine, 1994
- Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitroJournal of Cellular Physiology, 1993
- Inhibition of Matrix Metalloproteinase 9 Activation by a Specific Monoclonal AntibodyHybridoma, 1993
- Pathogenesis of giant cell arteritisArthritis & Rheumatism, 1993
- Are we losing focus on the internal elastic lamina in giant cell arteritis?Arthritis & Rheumatism, 1992
- Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development.Journal of Clinical Investigation, 1990
- Giant cell (cranial) arteritis: a clinical reviewAmerican Heart Journal, 1980
- A concept of diffuse actinic arteritis.British Journal of Dermatology, 1978
- ARTERITIS OF THE TEMPORAL VESSELSThe Lancet, 1938